iPrEX, carried out in Brazil (Fiocruz, UFRJ, and USP), was the first study of PrEP, which involved 2,499 HSH in Latin America, USA, South Africa, and Thailand. The participants, who took Truvada® via oral, had a rate 44% lower of infection by HIV when compared to those that took placebo. Among the patients with adhesion to the treatment, there was a reduction of 92% of the infections by HIV when compared to those volunteers with no detectable level of Truvada® in the visit of the study before the seroconversion.
For further information, access the website of the study: http://www.iprexole.com/indexpt.html
IPERGAY (França e Canadá)
This study is assessing if the use of Truvada® for PrEP shall be continuous or upon demand.
For further information, access: http://hivnet.ubc.ca/clinical-studies/canadian-hiv-trials-database /ctn268/
This study is assessing if the use of Truvada® for PrEP shall be immediate or 12 months after the advisory.
For further information, access:
This study is assessing of the use of Truvada® for PrEP in men that make sex with young men (15 to 22 years old).
For further information, access: http://www.projectprepare.net/
AIDES, França – http://www.aides.org/en/what-prep-2089
PrEP in CDC, USA: http://www.cdc.gov/hiv/prevention/research/prep/
PrEP Watch, USA: http://prepwatch.org/
AIDS Map, USA: http://www.aidsmap.com/PrEP/cat/1623/
Department of Health, USA: http://aids.gov/hiv-aids-basics/prevention/reduce-your-risk/pre-exposure-prophylaxis/